Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Preventing antimalarial drug resistance with triple artemisinin-based combination therapies

Tran Dang Nguyen, Bo Gao, Chanaki Amaratunga, Mehul Dhorda, Thu Nguyen-Anh Tran, Nicholas J White, Arjen M Dondorp, Maciej F Boni, View ORCID ProfileRicardo Aguas
doi: https://doi.org/10.1101/2022.10.21.22281347
Tran Dang Nguyen
1Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Gao
2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chanaki Amaratunga
2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
3Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mehul Dhorda
2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
3Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thu Nguyen-Anh Tran
1Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas J White
2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
3Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arjen M Dondorp
2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
3Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maciej F Boni
1Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA, USA
2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ricardo@tropmedres.ac mfb9@psu.edu
Ricardo Aguas
2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
3Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ricardo Aguas
  • For correspondence: ricardo@tropmedres.ac mfb9@psu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Increasing levels of artemisinin and partner drug resistance threaten malaria control and elimination globally. Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in areas of multidrug-resistant malaria. Whether early TACT adoption could delay the emergence and spread of antimalarial drug resistance is a question of vital importance.

Methods Using two independent individual-based models of Plasmodium falciparum epidemiology and evolution, we evaluated whether introduction of either artesunate-mefloquine-piperaquine or artemether-lumefantrine-amodiaquine resulted in lower long-term artemisinin-resistance levels and treatment failure rates compared with continued ACT use.

Findings In countries with 1% P. falciparum prevalence, immediate adoption of TACTs would result in substantially lower frequency of artemisinin-resistant alleles 10 years later. Median estimates were 70%, 33%, and 18% lower allele frequency for countries currently deploying dihydroartemisinin-piperaquine, artesunate-amodiaquine, or artemether-lumefantrine, respectively. Corresponding median treatment failure rate decreases are 74%, 34%, and 17%. Delaying TACT introduction increases future resistance frequencies and treatment failure rates. The most significant threat to the success of TACTs is the emergence of a triple-resistant genotype. which if above 0.01 frequency may undermine elimination efforts in low-prevalence regions.

Interpretation Introduction of TACTs could delay the emergence and spread of artemisinin resistance and treatment failure, extending the useful therapeutic life of current antimalarial drugs and improving the chances of malaria elimination. Immediate introduction of TACTs should be considered by policy makers in areas of emerging artemisinin resistance.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research falls under the auspices of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project funded by UK Aid and the UK Government Foreign, Commonwealth and Development Office. Funding from Wellcome Trust (220211) is also acknowledged. MFB, TDN, TN-AT acknowledge funding from the National Institutes of Health grant NIAID R01AI153355 and The Bill and Melinda Gates Foundation INV-005517 grant awarded to Pennsylvania State University. RA acknowledges funding from the Bill and Melinda Gates Foundation (OPP1193472).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced are available online at https://github.com/ATOME-MORU/deTACT

https://github.com/ATOME-MORU/deTACT

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted October 22, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
Tran Dang Nguyen, Bo Gao, Chanaki Amaratunga, Mehul Dhorda, Thu Nguyen-Anh Tran, Nicholas J White, Arjen M Dondorp, Maciej F Boni, Ricardo Aguas
medRxiv 2022.10.21.22281347; doi: https://doi.org/10.1101/2022.10.21.22281347
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
Tran Dang Nguyen, Bo Gao, Chanaki Amaratunga, Mehul Dhorda, Thu Nguyen-Anh Tran, Nicholas J White, Arjen M Dondorp, Maciej F Boni, Ricardo Aguas
medRxiv 2022.10.21.22281347; doi: https://doi.org/10.1101/2022.10.21.22281347

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10779)
  • Forensic Medicine (8)
  • Gastroenterology (583)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (864)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)